^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Adenocarcinoma

    Related cancers:
    1d
    OLIGOMETS: Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels (clinicaltrials.gov)
    P2, N=54, Recruiting, Yale University | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date • Circulating tumor DNA
    1d
    The Utility of SMAD4 and S100P as Diagnostic Immunohistochemical Markers for Pancreatic Ductal Adenocarcinomas in Egyptian Patients. (PubMed, J Microsc Ultrastruct)
    SMAD4 could be used as the diagnostic biomarker for pancreatic adenocarcinomas. There is combined classification accuracy of 98.9%, suggesting that they are a sensitive and specific approach for adenocarcinomas in limited material of EUS-FNAs and that combined panel approach was significantly more accurate than any other individual approach.
    Journal
    |
    SMAD4 (SMAD family member 4) • S100P (S100 calcium binding protein P)
    6d
    Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, Northwestern University | N=60 --> 500 | Trial completion date: Oct 2021 --> Oct 2029 | Trial primary completion date: Oct 2021 --> Oct 2027
    Enrollment change • Trial completion date • Trial primary completion date • Circulating tumor DNA
    6d
    TRIDENT: Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=80, Recruiting, Corcept Therapeutics | N=60 --> 80
    Enrollment change
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • Lifyorli (relacorilant)
    7d
    BATs Treatment for Pancreatic Cancer, Phase Ib/II (clinicaltrials.gov)
    P1/2, N=22, Completed, University of Virginia | Trial completion date: Jun 2025 --> Apr 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    8d
    Analysis and validation of abnormal signaling pathways and immune cell infiltration characteristics in digestive system cancers based on peroxisome-related genes. (PubMed, Biol Direct)
    Peroxisomes act as pivotal regulators of digestive cancer progression by modulating signaling pathways, the TIME, therapeutic resistance, and lipid metabolism. Targeting peroxisomal function, particularly in high-risk subgroups of HCC and CRC, warrants further exploration as a promising therapeutic strategy.
    Journal
    |
    PEX13 (Peroxisomal Biogenesis Factor 13)
    |
    Lenvima (lenvatinib)
    9d
    Lidocaine Infusion in Pancreatic Cancer (clinicaltrials.gov)
    P1, N=46, Recruiting, University of Illinois at Chicago | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial completion date • Trial primary completion date
    9d
    CLCA1 Modulates Pancreatic Cancer Proliferation via SIRT1-HIF-1α Pathway. (PubMed, Clin Lab)
    We found that CLCA1 modulates the SIRT1/HIF-1α pathway, suppressing tumor proliferation, and might enhance gemcitabine sensitivity in pancreatic cancer cells. This investigation points to CLCA1 as a viable therapeutic target for tackling hypoxia-induced chemoresistance and enhancing treatment success in PDAC. Further exploration of CLCA1-based therapies could offer new opportunities for clinical translation.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CLCA1 (Chloride Channel Accessory 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
    |
    gemcitabine
    12d
    Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, University of Washington
    New P1 trial
    |
    GATA6 (GATA Binding Protein 6) • HMGA2 (High mobility group AT-hook 2)
    |
    samuraciclib (CT7001)
    12d
    Targeting of MEK and Autophagy in Pancreatic Adenocarcinoma and Analysis of Treatment Sensitivity in Preclinical and Clinical Models: MEKiAUTO. (PubMed, JCO Precis Oncol)
    Combined MEK and autophagy inhibition showed limited tolerability in human PDAC. Divergent efficacy between preclinical and clinical settings likely reflects differences in tumor cell state heterogeneity between models. Integration of diverse, representative preclinical models is critical to guide development of effective therapies in PDAC.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • PDX1 (Pancreatic And Duodenal Homeobox 1)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    |
    Tecentriq (atezolizumab)
    12d
    Analysis of the Oncogenic Role of Colony-Stimulating Factor 1 Receptor (CSF1R) in Pancreatic Adenocarcinoma. (PubMed, Anticancer Agents Med Chem)
    Targeting CSF1R might be a PAAD treatment. Inhibiting CSF1R activity or TGF-β binding to CSF1R inhibits tumour growth and immune escape. Investigating the link between CSF1R, TGF-β, and the immune system opens new opportunities for combining targeted medicines with immunotherapy.
    Journal • IO biomarker
    |
    CSF1R (Colony stimulating factor 1 receptor) • TGFB1 (Transforming Growth Factor Beta 1)
    13d
    A Study Using 18F-FAZA and PET Scans to Study Hypoxia in Pancreatic Cancer (clinicaltrials.gov)
    P=N/A, N=48, Completed, University Health Network, Toronto | N=30 --> 48
    Enrollment change